Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis

Kevin Winthrop, Hisashi Yamanaka, Hernan Valdez, Eric Mortensen, Robert Chew, Sriram Krishnaswami, Thomas Kawabata, Richard Riese

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Objective Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) (i.e., shingles). The aim of this study was to determine whether treatment with tofacitinib increases the risk of HZ in patients with RA.

Methods HZ cases were identified as those reported by trial investigators from the databases of the phase II, phase III, and long-term extension (LTE) clinical trials in the Tofacitinib RA Development Program. Crude incidence rates (IRs) of HZ per 100 patient-years (with 95% confidence intervals [95% CIs]) were calculated by exposure group. Logistic regression analyses were performed to evaluate potential risk factors for HZ (e.g., age, prednisone use).

Results Among 4,789 participants, 239 were identified as having tofacitinib-associated HZ during the phase II, phase III, and LTE trials, of whom 208 (87%) were female and whose median age was 57 years (range 21-75 years). One HZ case (0.4%) was multidermatomal; none of the cases involved visceral dissemination or death. Twenty-four patients with HZ (10%) permanently discontinued treatment with tofacitinib, and 16 (7%) were either hospitalized or received intravenous antiviral drugs. The crude HZ IR across the development program was 4.4 per 100 patient-years (95% CI 3.8-4.9), but the IR was substantially higher within Asia (7.7 per 100 patient-years, 95% CI 6.4-9.3). Older age was associated with HZ (odds ratio 1.9, 95% CI 1.5-2.6), and IRs for HZ were similar between patients receiving 5 mg tofacitinib twice daily (4.4 per 100 patient-years, 95% CI 3.2-6.0) and those receiving 10 mg twice daily (4.2 per 100 patient-years, 95% CI 3.1-5.8). In the phase III trials among placebo recipients, the incidence of HZ was 1.5 per 100 patient-years (95% CI 0.5-4.6).

Conclusion In the Tofacitinib RA Development Program, increased rates of HZ were observed in patients treated with tofacitinib compared with those receiving placebo, particularly among patients within Asia. Complicated HZ among tofacitinib-treated patients was rare.

Original languageEnglish (US)
Pages (from-to)2675-2684
Number of pages10
JournalArthritis and Rheumatology
Volume66
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Herpes Zoster
Rheumatoid Arthritis
Confidence Intervals
Therapeutics
Incidence
tofacitinib
Placebos
Prednisone
Antiviral Agents

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Medicine(all)

Cite this

Winthrop, K., Yamanaka, H., Valdez, H., Mortensen, E., Chew, R., Krishnaswami, S., ... Riese, R. (2014). Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis and Rheumatology, 66(10), 2675-2684. https://doi.org/10.1002/art.38745

Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. / Winthrop, Kevin; Yamanaka, Hisashi; Valdez, Hernan; Mortensen, Eric; Chew, Robert; Krishnaswami, Sriram; Kawabata, Thomas; Riese, Richard.

In: Arthritis and Rheumatology, Vol. 66, No. 10, 01.10.2014, p. 2675-2684.

Research output: Contribution to journalArticle

Winthrop, K, Yamanaka, H, Valdez, H, Mortensen, E, Chew, R, Krishnaswami, S, Kawabata, T & Riese, R 2014, 'Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis', Arthritis and Rheumatology, vol. 66, no. 10, pp. 2675-2684. https://doi.org/10.1002/art.38745
Winthrop K, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis and Rheumatology. 2014 Oct 1;66(10):2675-2684. https://doi.org/10.1002/art.38745
Winthrop, Kevin ; Yamanaka, Hisashi ; Valdez, Hernan ; Mortensen, Eric ; Chew, Robert ; Krishnaswami, Sriram ; Kawabata, Thomas ; Riese, Richard. / Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. In: Arthritis and Rheumatology. 2014 ; Vol. 66, No. 10. pp. 2675-2684.
@article{0fd8ad47d1b34ee7bd7e491dcd09a382,
title = "Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis",
abstract = "Objective Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) (i.e., shingles). The aim of this study was to determine whether treatment with tofacitinib increases the risk of HZ in patients with RA.Methods HZ cases were identified as those reported by trial investigators from the databases of the phase II, phase III, and long-term extension (LTE) clinical trials in the Tofacitinib RA Development Program. Crude incidence rates (IRs) of HZ per 100 patient-years (with 95{\%} confidence intervals [95{\%} CIs]) were calculated by exposure group. Logistic regression analyses were performed to evaluate potential risk factors for HZ (e.g., age, prednisone use).Results Among 4,789 participants, 239 were identified as having tofacitinib-associated HZ during the phase II, phase III, and LTE trials, of whom 208 (87{\%}) were female and whose median age was 57 years (range 21-75 years). One HZ case (0.4{\%}) was multidermatomal; none of the cases involved visceral dissemination or death. Twenty-four patients with HZ (10{\%}) permanently discontinued treatment with tofacitinib, and 16 (7{\%}) were either hospitalized or received intravenous antiviral drugs. The crude HZ IR across the development program was 4.4 per 100 patient-years (95{\%} CI 3.8-4.9), but the IR was substantially higher within Asia (7.7 per 100 patient-years, 95{\%} CI 6.4-9.3). Older age was associated with HZ (odds ratio 1.9, 95{\%} CI 1.5-2.6), and IRs for HZ were similar between patients receiving 5 mg tofacitinib twice daily (4.4 per 100 patient-years, 95{\%} CI 3.2-6.0) and those receiving 10 mg twice daily (4.2 per 100 patient-years, 95{\%} CI 3.1-5.8). In the phase III trials among placebo recipients, the incidence of HZ was 1.5 per 100 patient-years (95{\%} CI 0.5-4.6).Conclusion In the Tofacitinib RA Development Program, increased rates of HZ were observed in patients treated with tofacitinib compared with those receiving placebo, particularly among patients within Asia. Complicated HZ among tofacitinib-treated patients was rare.",
author = "Kevin Winthrop and Hisashi Yamanaka and Hernan Valdez and Eric Mortensen and Robert Chew and Sriram Krishnaswami and Thomas Kawabata and Richard Riese",
year = "2014",
month = "10",
day = "1",
doi = "10.1002/art.38745",
language = "English (US)",
volume = "66",
pages = "2675--2684",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis

AU - Winthrop, Kevin

AU - Yamanaka, Hisashi

AU - Valdez, Hernan

AU - Mortensen, Eric

AU - Chew, Robert

AU - Krishnaswami, Sriram

AU - Kawabata, Thomas

AU - Riese, Richard

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Objective Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) (i.e., shingles). The aim of this study was to determine whether treatment with tofacitinib increases the risk of HZ in patients with RA.Methods HZ cases were identified as those reported by trial investigators from the databases of the phase II, phase III, and long-term extension (LTE) clinical trials in the Tofacitinib RA Development Program. Crude incidence rates (IRs) of HZ per 100 patient-years (with 95% confidence intervals [95% CIs]) were calculated by exposure group. Logistic regression analyses were performed to evaluate potential risk factors for HZ (e.g., age, prednisone use).Results Among 4,789 participants, 239 were identified as having tofacitinib-associated HZ during the phase II, phase III, and LTE trials, of whom 208 (87%) were female and whose median age was 57 years (range 21-75 years). One HZ case (0.4%) was multidermatomal; none of the cases involved visceral dissemination or death. Twenty-four patients with HZ (10%) permanently discontinued treatment with tofacitinib, and 16 (7%) were either hospitalized or received intravenous antiviral drugs. The crude HZ IR across the development program was 4.4 per 100 patient-years (95% CI 3.8-4.9), but the IR was substantially higher within Asia (7.7 per 100 patient-years, 95% CI 6.4-9.3). Older age was associated with HZ (odds ratio 1.9, 95% CI 1.5-2.6), and IRs for HZ were similar between patients receiving 5 mg tofacitinib twice daily (4.4 per 100 patient-years, 95% CI 3.2-6.0) and those receiving 10 mg twice daily (4.2 per 100 patient-years, 95% CI 3.1-5.8). In the phase III trials among placebo recipients, the incidence of HZ was 1.5 per 100 patient-years (95% CI 0.5-4.6).Conclusion In the Tofacitinib RA Development Program, increased rates of HZ were observed in patients treated with tofacitinib compared with those receiving placebo, particularly among patients within Asia. Complicated HZ among tofacitinib-treated patients was rare.

AB - Objective Patients with rheumatoid arthritis (RA) are at increased risk for herpes zoster (HZ) (i.e., shingles). The aim of this study was to determine whether treatment with tofacitinib increases the risk of HZ in patients with RA.Methods HZ cases were identified as those reported by trial investigators from the databases of the phase II, phase III, and long-term extension (LTE) clinical trials in the Tofacitinib RA Development Program. Crude incidence rates (IRs) of HZ per 100 patient-years (with 95% confidence intervals [95% CIs]) were calculated by exposure group. Logistic regression analyses were performed to evaluate potential risk factors for HZ (e.g., age, prednisone use).Results Among 4,789 participants, 239 were identified as having tofacitinib-associated HZ during the phase II, phase III, and LTE trials, of whom 208 (87%) were female and whose median age was 57 years (range 21-75 years). One HZ case (0.4%) was multidermatomal; none of the cases involved visceral dissemination or death. Twenty-four patients with HZ (10%) permanently discontinued treatment with tofacitinib, and 16 (7%) were either hospitalized or received intravenous antiviral drugs. The crude HZ IR across the development program was 4.4 per 100 patient-years (95% CI 3.8-4.9), but the IR was substantially higher within Asia (7.7 per 100 patient-years, 95% CI 6.4-9.3). Older age was associated with HZ (odds ratio 1.9, 95% CI 1.5-2.6), and IRs for HZ were similar between patients receiving 5 mg tofacitinib twice daily (4.4 per 100 patient-years, 95% CI 3.2-6.0) and those receiving 10 mg twice daily (4.2 per 100 patient-years, 95% CI 3.1-5.8). In the phase III trials among placebo recipients, the incidence of HZ was 1.5 per 100 patient-years (95% CI 0.5-4.6).Conclusion In the Tofacitinib RA Development Program, increased rates of HZ were observed in patients treated with tofacitinib compared with those receiving placebo, particularly among patients within Asia. Complicated HZ among tofacitinib-treated patients was rare.

UR - http://www.scopus.com/inward/record.url?scp=84908370285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908370285&partnerID=8YFLogxK

U2 - 10.1002/art.38745

DO - 10.1002/art.38745

M3 - Article

C2 - 24943354

AN - SCOPUS:84908370285

VL - 66

SP - 2675

EP - 2684

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -